This amount is in addition to the nearly $12 million in series B financing the company recently raised. It plans to use the funds for two clinical trials to further prove the efficacy of Mi-eye, Trice Medical’s proprietary visualization device. The FDA-cleared device aims to help physicians perform diagnostic arthroscopies, according to the report.
More articles on devices:
5 things to know about the SpineGuard “smart screw” European patent
Medtronic Spinal employees rack-up 4.8k charitable hours — 5 things to know
X-Bolt Orthopaedics receives U.S. patent for jig device in hip nailing system
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
